The FDA approved fam-trastuzumab-deruxtecan-nxki, (Enhertu, Daiichi-Sankyo/AstraZeneca) for the treatment of patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy for patients with the newly defined HER2-low breast cancer subtype of HER2-negative breast cancer.
Patients with HER2-low breast cancer are eligible for trastuzumab deruxtecan if they have received prior chemotherapy in the metastatic setting or their cancer returned during or within